STOK ▲ +0.8% - Stoke Therapeutics, Inc. $STOK Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Stoke Therapeutics rose 0.8% following an announcement that the company and partner Biogen will present clinical data on zorevunersen, an investigational treatment for Dravet Syndrome, at the European Epilepsy Congress. The presentation of late-stage trial results for a rare neurological condition typically attracts investor interest in biotech companies developing therapies for serious unmet medical needs. 01-SEP-2026 07:30 AM ET